Is 2’-FL HMO Associated With Reduced Occurrence of Eczema?

Barbara J. Marriage, PhD, RD
Associate Director
Regulatory Science & Innovation, Abbott Nutrition

Rachael H. Buck, PhD
Associate Research Fellow
Global R&D, Abbott Nutrition

Scientific Overview

Based on emerging evidence of the important role Human Milk Oligosaccharides (HMOs) have as immune nourishing ingredients, scientists are beginning to investigate the therapeutic potential of HMOs for allergies. In 2015, Marriage and colleagues conducted the first clinical intervention trial to examine the growth and tolerance of infants fed a formula supplemented with 2’-fucosyllactose (2’-FL) HMO in healthy term infants (n=79 control formula, no 2’-FL; n=70 experimental formula, 0.2g/L and 1.0g/L 2’-FL; n=83 breastmilk). The randomized, controlled growth and tolerance trial showed growth and 2’-FL absorption similar to breastfed infants when feeding infant formulas fortified with 2’-FL HMO. Further, an analysis of adverse event reporting found that infants fed formula with 2’-FL HMO had less eczema than the infants fed control formula without 2’-FL HMO and similar to breastfed infants.

Applying to Your Practice

Formulas With 2’-FL HMO Support Important Immune Development

HMOs play multiple roles to help protect baby’s digestive and immune health. 2’-FL HMO helps support the developing immune system and is associated with reduced incidence of gastrointestinal and respiratory illness and less risk of eczema.

Key Takeaways

Recommend Formulas With 2’-FL HMO to Strengthen Baby’s Immune System Like Breastfed Infants

1. HMOs support the developing immune system and are associated with reduced incidence of gastrointestinal and respiratory illness and less risk of eczema.
2. Infant formulas containing 2’-FL HMO help strengthen the immune system to be more like breastfed infants.

References: